WO2005097079A3 - Controlled release dosage for gaba receptor agonist - Google Patents

Controlled release dosage for gaba receptor agonist Download PDF

Info

Publication number
WO2005097079A3
WO2005097079A3 PCT/US2005/011032 US2005011032W WO2005097079A3 WO 2005097079 A3 WO2005097079 A3 WO 2005097079A3 US 2005011032 W US2005011032 W US 2005011032W WO 2005097079 A3 WO2005097079 A3 WO 2005097079A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor agonist
controlled release
release dosage
gaba receptor
gabab
Prior art date
Application number
PCT/US2005/011032
Other languages
French (fr)
Other versions
WO2005097079A2 (en
Inventor
Chien-Hsuan Han
Ann Hsu
Larry Hsu
Charles Hsiao
Ching-Ling Diana Teng
Original Assignee
Impax Laboratories Inc
Chien-Hsuan Han
Ann Hsu
Larry Hsu
Charles Hsiao
Ching-Ling Diana Teng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/815,926 external-priority patent/US20050220873A1/en
Priority claimed from US10/815,929 external-priority patent/US20050220864A1/en
Priority claimed from US10/815,924 external-priority patent/US20050220863A1/en
Priority claimed from US10/815,930 external-priority patent/US20050220874A1/en
Priority to EP05733181A priority Critical patent/EP1729740A2/en
Priority to JP2007506301A priority patent/JP2007531727A/en
Application filed by Impax Laboratories Inc, Chien-Hsuan Han, Ann Hsu, Larry Hsu, Charles Hsiao, Ching-Ling Diana Teng filed Critical Impax Laboratories Inc
Priority to CA002560995A priority patent/CA2560995A1/en
Priority to BRPI0509399-6A priority patent/BRPI0509399A/en
Priority to MXPA06011322A priority patent/MXPA06011322A/en
Priority to AU2005231433A priority patent/AU2005231433A1/en
Publication of WO2005097079A2 publication Critical patent/WO2005097079A2/en
Publication of WO2005097079A3 publication Critical patent/WO2005097079A3/en
Priority to IL178296A priority patent/IL178296A0/en
Priority to NO20065013A priority patent/NO20065013L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Abstract

The present invention relates generally to pharmaceutical dosage forms having immediate release and controlled release properties that contain a Ϝ-aminobutyric acid (GABAB) receptor agonist, e.g., baclofen, for the treatment of medical conditions, which includes spasms, cramping, and tightness of muscles, associated with ailments such as multiple sclerosis or certain spinal injuries.
PCT/US2005/011032 2004-04-02 2005-04-01 Controlled release dosage for gaba receptor agonist WO2005097079A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2005231433A AU2005231433A1 (en) 2004-04-02 2005-04-01 Controlled release dosage for GABA receptor agonist
MXPA06011322A MXPA06011322A (en) 2004-04-02 2005-04-01 Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a gabab.
BRPI0509399-6A BRPI0509399A (en) 2004-04-02 2005-04-01 pharmaceutical dosage form
CA002560995A CA2560995A1 (en) 2004-04-02 2005-04-01 Controlled release dosage for gaba receptor agonist
JP2007506301A JP2007531727A (en) 2004-04-02 2005-04-01 Pharmaceutical dosage form with immediate and / or controlled release properties containing a GABAB receptor agonist
EP05733181A EP1729740A2 (en) 2004-04-02 2005-04-01 PHARMACEUTICAL DOSAGE FORMS HAVING IMMEDIATE RELEASE AND/OR CONTROLLED RELEASE PROPERTIES THAT CONTAIN A GABA<SB>B</SB> RECEPTOR AGONIST
IL178296A IL178296A0 (en) 2004-04-02 2006-09-26 Pharmaceutical compositions containing a gaba?? receptor agonist
NO20065013A NO20065013L (en) 2004-04-02 2006-11-01 Controlled release dosage for GABA receptor agonist

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US10/815,926 US20050220873A1 (en) 2004-04-02 2004-04-02 Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
US10/815,930 US20050220874A1 (en) 2004-04-02 2004-04-02 Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US10/815,930 2004-04-02
US10/815,926 2004-04-02
US10/815,924 2004-04-02
US10/815,924 US20050220863A1 (en) 2004-04-02 2004-04-02 Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US10/815,929 US20050220864A1 (en) 2004-04-02 2004-04-02 Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US10/815,929 2004-04-02

Publications (2)

Publication Number Publication Date
WO2005097079A2 WO2005097079A2 (en) 2005-10-20
WO2005097079A3 true WO2005097079A3 (en) 2006-01-05

Family

ID=35060819

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/011032 WO2005097079A2 (en) 2004-04-02 2005-04-01 Controlled release dosage for gaba receptor agonist

Country Status (11)

Country Link
EP (1) EP1729740A2 (en)
JP (1) JP2007531727A (en)
KR (1) KR20070020022A (en)
AU (1) AU2005231433A1 (en)
BR (1) BRPI0509399A (en)
CA (1) CA2560995A1 (en)
IL (1) IL178296A0 (en)
MX (1) MXPA06011322A (en)
NO (1) NO20065013L (en)
TW (1) TW200536523A (en)
WO (1) WO2005097079A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010515754A (en) * 2007-01-11 2010-05-13 ゼノポート，インコーポレイティド Sustained release oral dosage form of prodrug of R-baclofen and method of treatment
WO2009096985A1 (en) * 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
EP2403486A1 (en) 2009-03-03 2012-01-11 XenoPort, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
RU2672884C1 (en) * 2017-11-07 2018-11-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский государственный педагогический университет им. А.И. Герцена" (РГПУ им. А.И. Герцена) Agent for preserving population of gaba-ergic neurons after acute perinatal hypoxia
JP7138666B2 (en) * 2018-01-24 2022-09-16 大原薬品工業株式会社 METHOD FOR IMPROVING CHEMICAL STABILITY OF TABLETS CONTAINING γ-AMINOBUTYRIC ACID DERIVATIVES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719185A (en) * 1993-04-23 1998-02-17 Glaxo Group Limited Use for GABA agonists for treating emesis
US6544998B2 (en) * 2000-11-30 2003-04-08 Pfizer Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719185A (en) * 1993-04-23 1998-02-17 Glaxo Group Limited Use for GABA agonists for treating emesis
US6544998B2 (en) * 2000-11-30 2003-04-08 Pfizer Inc Combination of gaba agonists and sorbitol dehydrogenase inhibitors

Also Published As

Publication number Publication date
MXPA06011322A (en) 2007-02-21
WO2005097079A2 (en) 2005-10-20
KR20070020022A (en) 2007-02-16
IL178296A0 (en) 2007-02-11
NO20065013L (en) 2007-01-02
BRPI0509399A (en) 2007-09-18
TW200536523A (en) 2005-11-16
EP1729740A2 (en) 2006-12-13
JP2007531727A (en) 2007-11-08
CA2560995A1 (en) 2005-10-20
AU2005231433A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
WO2006128070A3 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a gabab receptor agonist
WO2007016538A3 (en) Preparation and use of biphenyl amino acid derivatives for the treatment of obesity
WO2008033455A3 (en) Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
EP2308841A3 (en) Phlorizin analogs as SGLT2 inhibitors
WO2006055625A3 (en) Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
WO2006044775A3 (en) Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
WO2008010222A3 (en) Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof and their use in treating cns disorders
WO2002100347A3 (en) Prodrugs of gaba analogs, compositions and uses thereof
PL2148670T3 (en) Titration of tapentadol
WO2010022055A3 (en) 1, 3, 5 -triaz ine derivatives useful in the treatment of chronic pain disorders
WO2007009894A3 (en) Peptides for use in the treatment of obesity
WO2005097079A3 (en) Controlled release dosage for gaba receptor agonist
WO2006055725A3 (en) Substituted amino acids as protein tyrosine phosphatase inhibitors
WO2004099171A3 (en) Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
WO2003059291A3 (en) Treatment of bone disorders with skeletal anabolic drugs
WO2007017764A3 (en) Substituted benzimidazole compounds with dual nos inhibitory activity and muopioid agonist activity
WO2009116037A3 (en) NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801
WO2008075173A3 (en) Methods for treating podocyte-related disorders
WO2007006732A8 (en) Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
WO2006138372A3 (en) Methods and reagents for the treatment of inflammatory disorders
WO2008087189A3 (en) Peptides for use in the treatment of obesity
WO2007110709A8 (en) Formulations of tipifarnib for intravenous administration
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2560995

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005231433

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2794/KOLNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 178296

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200580010839.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2006/08190

Country of ref document: ZA

Ref document number: 2007506301

Country of ref document: JP

Ref document number: PA/a/2006/011322

Country of ref document: MX

Ref document number: 200608190

Country of ref document: ZA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2005733181

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005231433

Country of ref document: AU

Date of ref document: 20050401

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005231433

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067022957

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006138614

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005733181

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067022957

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0509399

Country of ref document: BR